OLMA

SEC source: 0001415889-24-018975 · form4-07022024_050720.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 761,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $10.77, and the range of prices was between $10.55 and $11.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000921895-24-001437 · form407422010_06182024.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · Director · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · Director · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · 10% owner

BVF INC/IL · CIK 0001056807 · Director · 10% owner

LAMPERT MARK N · CIK 0001233840 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 23,000

Underlying: Common stock, $0.0001 par value · 23,000 shares

Expires 2034-06-14

F6 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F7 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.

F6 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F6 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-017447 · form4-06182024_050618.xml · derivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017444 · form4-06182024_050611.xml · derivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017441 · form4-06182024_050605.xml · derivative · entry 1

BUTITTA CYNTHIA M · CIK 0001222082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017440 · form4-06182024_050602.xml · derivative · entry 1

CLARK IAN T · CIK 0001336504 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017442 · form4-06182024_050607.xml · derivative · entry 1

Garland J. Scott · CIK 0001533228 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017448 · form4-06182024_050620.xml · derivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017443 · form4-06182024_050609.xml · derivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017446 · form4-06182024_050616.xml · derivative · entry 1

Larson Yi · CIK 0001785987 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001415889-24-017445 · form4-06182024_050613.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

F2 · ownership.direct: The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001415889-24-015508 · form4-06042024_090601.xml · nonDerivative · entry 3

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 781,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F4 · price: The weighted average sale price for the transaction reported was $12.33, and the range of prices was between $12.23 and $12.43. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0000935836-24-000425 · ownership.xml · nonDerivative · entry 2

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 708,114

F2 · ownership.nature: The shares are held by Logos Opportunities Fund II LP ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000935836-24-000425 · ownership.xml · nonDerivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 700,761

F1 · ownership.nature: The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000935836-24-000744 · ownership.xml · nonDerivative · entry 2

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 708,114

F2 · ownership.nature: The shares are held by Logos Opportunities Fund II LP ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000935836-24-000744 · ownership.xml · nonDerivative · entry 1

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 700,761

F1 · ownership.nature: The shares are held by Logos Opportunities Fund I LP ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the reporting person is a managing member of Logos Opportunities GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0001415889-24-015508 · form4-06042024_090601.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 786,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F3 · price: The weighted average sale price for the transaction reported was $10.93, and the range of prices was between $10.91 and $11.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-015508 · form4-06042024_090601.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 791,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $9.41, and the range of prices was between $9.34 and $9.56. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-014689 · form4-05282024_050502.xml · derivative · entry 2

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,840

Underlying: Common Stock · 9,460 shares

Expires 2033-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-014689 · form4-05282024_050502.xml · nonDerivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-012485 · form4-05072024_050502.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 806,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $10.92, and the range of prices was between $10.91 and $10.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-012020 · form4-05022024_090504.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 811,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $9.51, and the range of prices was between $9.20 and $9.91. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-009445 · form4-03292024_050302.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 826,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $10.97, and the range of prices was between $10.80 and $11.20. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-008762 · form4-03202024_050301.xml · derivative · entry 2

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,300

Underlying: Common Stock · 13,700 shares

Expires 2033-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-008762 · form4-03202024_050301.xml · nonDerivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-007081 · form4-03062024_100356.xml · nonDerivative · entry 2

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 385,965

F1 · kind: Pro rata distribution for no consideration from SPW Investments LLC ("SPWI") to its members. Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI.

F3 · ownership.nature: The shares are held by the Rappaport Family Trust, of which the reporting person is co-trustee.

SEC source: 0001415889-24-007081 · form4-03062024_100356.xml · nonDerivative · entry 1

RAPPAPORT ANDREW · CIK 0001162157 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: Pro rata distribution for no consideration from SPW Investments LLC ("SPWI") to its members. Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI.

F2 · ownership.nature: The shares were held by SPWI.

SEC source: 0001415889-24-006322 · form4-03042024_050305.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 846,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F3 · price: The weighted average sale price for the transaction reported was $13.00, and the range of prices was between $12.97 and $13.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-006322 · form4-03042024_050305.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 846,383

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $12.41, and the range of prices was between $11.94 and $12.86. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-002350 · form4-02022024_050201.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 871,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F3 · price: The weighted average sale price for the transaction reported was $15.56, and the range of prices was between $15.55 and $15.59. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-002608 · form4-02052024_050206.xml · derivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,500

Underlying: Common Stock · 304,500 shares

Expires 2034-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-002610 · form4-02052024_050218.xml · derivative · entry 1

Myles David C. · CIK 0001831216 · CH. DISCOV. & NON-CLIN DEV OFF

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-002609 · form4-02052024_050213.xml · derivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2034-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-002607 · form4-02052024_050202.xml · derivative · entry 1

Bohen Sean · CIK 0001831218 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 621,500

Underlying: Common Stock · 621,500 shares

Expires 2034-01-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-002350 · form4-02022024_050201.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 876,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $12.23, and the range of prices was between $12.03 and $12.38. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-001896 · form4-01292024_070101.xml · derivative · entry 2

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,000

Underlying: Common Stock · 20,000 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-001896 · form4-01292024_070101.xml · nonDerivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-001062 · form4-01162024_070101.xml · derivative · entry 2

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,000

Underlying: Common Stock · 50,000 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-24-001062 · form4-01162024_070101.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 484,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-000070 · form4-01022024_050101.xml · nonDerivative · entry 2

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 901,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F3 · price: The weighted average sale price for the transaction reported was $14.10, and the range of prices was between $14.08 and $14.27. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-000070 · form4-01022024_050101.xml · nonDerivative · entry 1

Harmon Cyrus · CIK 0001831410 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 903,783

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

F2 · price: The weighted average sale price for the transaction reported was $13.30, and the range of prices was between $13.15 and $13.87. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-23-016322 · form4-12122023_051203.xml · derivative · entry 2

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,000

Underlying: Common Stock · 10,000 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-23-016322 · form4-12122023_051203.xml · nonDerivative · entry 1

Kovacs Shane William Charles · CIK 0001579397 · CH. OPERATING & FINANCIAL OFF.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 434,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-016321 · form4-12122023_051201.xml · derivative · entry 2

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,000

Underlying: Common Stock · 2,900 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-23-016321 · form4-12122023_051201.xml · nonDerivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,664

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-015993 · form4-12082023_011253.xml · derivative · entry 2

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,900

Underlying: Common Stock · 13,100 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

SEC source: 0001415889-23-015993 · form4-12082023_011253.xml · nonDerivative · entry 1

Zojwalla Naseem · CIK 0001905871 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-23-124717 · tm2332400d1_4seq1.xml · nonDerivative · entry 1

Paradigm Biocapital Advisors LP · CIK 0001855655 · 10% owner

Paradigm BioCapital Advisors GP LLC · CIK 0001994082 · 10% owner

Paradigm BioCapital International Fund Ltd. · CIK 0001854392 · 10% owner

Asefaw Senai · CIK 0001994183 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Paradigm BioCapital International Fund Ltd.

Disclosed balance after: 6,590,981

F1 · ownership.nature: These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.

SEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 4

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 1,800,000

F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

SEC source: 0000935836-23-000733 · ownership.xml · nonDerivative · entry 3

Graham G. Walmsley · CIK 0001777517 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See note

Disclosed balance after: 1,750,000

F1 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the reporting person is a managing member of Logos GP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.